Finance

$ORCL fell 8% after reporting negative free cash flow of $23.7B for fiscal 2026 and a plan to raise $40B through debt and equity, even as Q4 revenue and EPS topped LSEG estimates.

$PSKY traded about 3% higher after hours after the DOJ cleared Paramount Skydance’s proposed acquisition of $WBD, a roughly $110B transaction that still awaits EU review and could face state-level challenges.

$SPCX closed at $160.95, up more than 19% from its $135 IPO price, putting SpaceX near a $2.1T market value after more than 500M shares traded in its first Nasdaq session.

Chow Tai Fook (1929.HK) rose 15% after FY2026 profit attributable to shareholders increased 52.2% to HK$9.004B. The company reported revenue of HK$94.398B, gross margin of 32.3% and operating profit margin of 20.0%.

Oracle $ORCL fell as much as 11% after Q4 results, with CNBC citing investor concern over a FY2027 funding plan of about $40B. Oracle’s release showed FY2026 free cash flow at negative $23.7B, RPO of $638B and Q4 non-GAAP EPS of $2.11.

SpaceX priced 555,555,555 Class A shares at $135, raising about $75B before a June 12 Nasdaq debut under $SPCX. The company also granted underwriters a 30-day option for 83,333,333 additional shares, making the offering a benchmark event for IPO and index investors.

Hugo Boss shares rose 8% after Frasers Group launched a $2B takeover offer, according to CNBC. Frasers already owns roughly 26% of the German fashion group, making the bid a material European retail M&A event.

U.S. producer prices rose 1.1% in May, above the 0.7% Dow Jones consensus cited by CNBC. The surprise puts energy-sensitive inflation back in focus for Fed pricing and Treasury-market positioning.

Super Micro Computer $SMCI fell 9% in extended trading after proposing $7.0B of equity and equity-linked financing. The company tied the capital raise to about $39B of recent AI-server orders from more than 20 customers.

Bank Indonesia raised the BI-Rate by 25 bps to 5.50%, with the Deposit Facility at 4.50% and Lending Facility at 6.25%. The off-cycle move followed rupiah weakness and foreign portfolio outflows.

GSK $GSK agreed to acquire Nuvalent $NUVL for $10.6B in cash, offering $124 a share and a 40% premium to Nuvalent’s prior close. The transaction gives GSK two late-stage lung-cancer assets under U.S. FDA review for 2026 approvals.

Zealand Pharma $ZLDPF fell more than 24% after full Phase III survodutide data showed GI-event discontinuations of 19% versus 2.9% on placebo. The same program showed up to 16.6% weight loss, 34% visceral-fat reduction, and 63.1% liver-fat reduction.